Jeffry G Weers

USPTO Granted Patents = 60 (Patent Applications = 10)

CIPO Patents = 6 (Patent Applications = 5)

EPO Patents = 9 (Patent Applications = 9)

Average Co-Inventor Count = 4.0

ph-index = 19

Forward Citations = 1,663(Granted Patents)

Location History:

San Diego, CA (US) (1996 - 2012)
Belmont, CA (US) (2011 - 2020)
Half Moon Bay, CA (US) (2001 - 2022)

Company Filing History:

20 out of 92

Alliance Pharmaceutical Corp.

Respira Therapeutics, Inc.

patents

5. 3 out of 57

Inhale Therapeutic Systems, Inc.

patents

6. 3 out of 6

Imcor Pharmaceutical Company

University of Illinois

patents

9. 1 out of 1

Cystetic Medicines, Inc.

patent

10. 3 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1996-2025

Loading Chart...

60 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12419899 - Ion channel prosthetic compositions comprising lipid-coated crystals of amphotericin B (2025-09-23),

2. 12263174 - Methods and compositions for treatment of pulmonary hypertension and other lung disorders (2025-04-01),

3. 11491161 - Methods and compositions for treatment of pulmonary hypertension and other lung disorders (2022-11-08),

4. 11491160 - Methods and compositions for treatment of pulmonary hypertension and other lung disorders (2022-11-08),

5. 10912778 - Methods for treatment of pulmonary hypertension (2021-02-09),

6. 10744098 - Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients (2020-08-18),

7. 9744318 - Aerosolization apparatus for inhalation profile-independent drug delivery (2017-08-29),

8. 9744178 - Respirable agglomerates of porous carrier particles and micronized drug (2017-08-29),

9. 9452139 - Respirable agglomerates of porous carrier particles and micronized drug (2016-09-27),

10. 9439862 - Phospholipid-based powders for drug delivery (2016-09-13),

11. 9421166 - Pulmonary delivery of aminoglycoside (2016-08-23),

12. 9155732 - Pulmonary delivery of a fluoroquinolone (2015-10-13),

13. 9050267 - Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases (2015-06-09),

14. 8877162 - Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery (2014-11-04),

15. 8834930 - Pulmonary delivery of a fluoroquinolone (2014-09-16),

Title: Innovator Spotlight: Jeffry G Weers

Introduction:

Jeffry G Weers, based in San Diego, California, is a notable inventor with an impressive portfolio of 33 patents. His work primarily centers around the development of engineered particles and methods for delivering bioactive agents to the respiratory tract, contributing significantly to innovations in respiratory therapies.

Latest Patents:

Among his latest inventions, Weers has developed methods for using engineered particles designed for the delivery of bioactive agents. These particles can be utilized either as dry powders or in stabilized dispersions comprising a nonaqueous continuous phase. A significant aspect of his innovation is the potential application of these particles with inhalation devices such as dry powder inhalers, metered dose inhalers, or nebulizers.

Additionally, Weers has created a respiratory dispersion aimed at the pulmonary delivery of at least two bioactive agents. This invention includes a propellant suspension medium that contains dispersed perforated microstructures, with each agent incorporated into individual structures, enhancing the effectiveness of the delivery system.

Career Highlights:

Throughout his career, Jeffry G Weers has been associated with reputable companies such as Alliance Pharmaceutical Corporation and Nektar Therapeutics. His extensive experience in the pharmaceutical industry has allowed him to make substantial advancements in the field of respiratory therapies.

Collaborations:

Weers has collaborated with prominent professionals, including Ernest George Schutt and Thomas E Tarara, sharing insights and expertise to further enhance his innovative projects. These collaborations contribute to the successful development of his patented technologies.

Conclusion:

Jeffry G Weers stands out as a significant figure in the realm of biomedical innovations, particularly in respiratory health. With a solid portfolio of patents and impactful collaborations, he continues to contribute to advancements in health care technology, paving the way for new treatments and improved patient outcomes.

This text is generated by artificial intelligence and may not be accurate.